A trusted partner
of biopharma clinical development and translational research teams.
Pathlight is being used in clinical studies by multiple top 10 pharmaceutical companies and leading academic institutions and national cancer centers.
Our Approach
to Partnership
SAGA is a trusted and experienced precision diagnostics partner, with proven expertise in research and regulated studies equipped with leading ctDNA-based liquid biopsy solutions for solid tumors and hematologic malignancies. Our biopharma testing services deliver exceptional sensitivity and specificity for all stages of drug development and commercialization.
We partner with biopharma companies of all sizes and stages of development to enable efficient, cost-effective research studies and tailored clinical trial support to accelerate biomarker discovery, trial enrollment, and time to commercialization.
Purpose-built to overcome the sensitivity, high-cost and long turnaround times of MRD tests, Pathlight uses low-pass whole genome sequencing to identify large-scale genomic changes, called structural variants (SVs), and tracks them over time using a unique combination of NGS and digital PCR, enabling industry-leading sensitivity and specificity. By optimizing for SVs that are stable, truncal biomarkers, Pathlight enables ultrasensitive ctDNA detection and quantification in the landmark, recurrence and treatment response monitoring settings, providing utility from early-stage to metastatic disease.
Our biopharma services using Pathlight enable:
a larger window of opportunity for ctDNA-guided trials with demonstrated lead times to clinical recurrence of >5 years in early-stage breast cancer
a more complete, and faster, understanding of therapy response in early-stage drug trials vs. RECIST
identification of more high-risk, ctDNA positive patients for stratification and more efficient clinical trial enrollment
near real-time monitoring of treatment response for more rapid and accurate randomization and adaptive trial management
the ability to assess ctDNA at more timepoints on the same budget
insight into SV-influenced mechanisms of drug efficacy and resistance
We partner with biopharma companies of all sizes and stages of development to enable efficient, cost-effective research studies and tailored clinical trial support to accelerate biomarker discovery, trial enrollment, and time to commercialization.
Purpose-built to overcome the sensitivity, high-cost and long turnaround times of MRD tests, Pathlight uses low-pass whole genome sequencing to identify large-scale genomic changes, called structural variants (SVs), and tracks them over time using a unique combination of NGS and digital PCR, enabling industry-leading sensitivity and specificity. By optimizing for SVs that are stable, truncal biomarkers, Pathlight enables ultrasensitive ctDNA detection and quantification in the landmark, recurrence and treatment response monitoring settings, providing utility from early-stage to metastatic disease.
Our biopharma services using Pathlight enable:
a larger window of opportunity for ctDNA-guided trials with demonstrated lead times to clinical recurrence of >5 years in early-stage breast cancer
a more complete, and faster, understanding of therapy response in early-stage drug trials vs. RECIST
identification of more high-risk, ctDNA positive patients for stratification and more efficient clinical trial enrollment
near real-time monitoring of treatment response for more rapid and accurate randomization and adaptive trial management
insight into SV-influenced mechanisms of drug efficacy and resistance
Let’s work together
We welcome partnerships with biopharma companies, research institutions, and care providers who share our mission to intercept cancer at the earliest stages when it’s most treatable.